UNSPSC 51202803: Sirolimus

This classification denotes a bcar2 gene, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W36ZG6FT64. European Medicines Agency schedules Rapamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10537MIG. Sirolimus generally arises in the molecular formula C51H79NO13.

The term SIROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34.) SIROLIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule sirolimus under HS 29349990 and SITC 51579. As of Q4 2014, SIROLIMUS remains US FDA's Preferred Term for this commodity. Sirolimus bears US NLM identifiers UMLS ID C0072980 and NCI Concept Code C1212.

UNSPSC 51202803 Sirolimus, a Commodity code, represents pharmaceutical products that state and local governments procure through warehouse and supply contracts, typically leveraging cooperative purchasing vehicles and piggyback arrangements to secure pricing on branded and generic medications. The code captures acquisition of specific pharmaceutical compounds by state health departments, county health systems, and public safety agencies for clinical, emergency response, and community health purposes. Recent state and local solicitations under this code reflect a mix of routine pharmaceutical supply procurement—including immunosuppressants, antibiotics, and emergency-response medications—sourced through established consortium frameworks and competitive bidding processes with fixed-term contracts and renewal options.

Illinois Department of Public Health and Seminole County, Florida represent the issuing-body mix, though the recent opportunities show limited direct sirolimus activity; the Illinois contract awarded to Chartwell Rx LLC on August 28, 2026 for antibiotic supply ($2,999,999.11 over three years) used an Invitation for Bid process through the MMCAP Infuse cooperative purchasing consortium, while Seminole County's IFB60459723LAS (response deadline July 26, 2023) sought naloxone and drug deactivation systems with quarterly delivery requirements. Geographic activity is concentrated in the Southeast and Midwest, with Florida and Illinois representing recent documented procurement. The Illinois award demonstrates the operational structure: multi-year initial terms with renewal options, quarterly or routine delivery schedules, inclusion of all shipping in vendor pricing, and selection on a lowest-priced responsive-and-responsible basis. State and local pharmaceutical procurement under this code typically does not require set-aside compliance or domestic-product preferences, though FEMA-funded acquisitions may introduce additional federal compliance layers including clean-air and water-pollution control adherence.